Evidence based decision making for the rational drug list (RDL)

EVIDENCE BASED DECISION MAKING FOR THE RATIONAL DRUG LIST (RDL) DR MAISA AL SAKET DG JOINT PROCUREMENT DEPARTMENT Committee 2 Evidence Based MeTA 10/06/09

Members of Committee 2
Dr Maisa Al Saket/ G.D. - JPD
Dr Riham Al Natheef/ Supply Director- RMS
Dr Musallam Qatarneh/ Purchasing & Supply Director/ MOH
Dr Ibrahim Abbadi/ Jordan University
Dr Lama Al Homoud/ Clinical Pharmacy Director - MOH
Dr Hanan Sboul/ SG. - JAPM
10/06/09 MeTA

Background
There will be a transparent evidence- based process in place for listing drugs
Conducting Pharmaco-economic studies is crucial for the development of an effective and affordable national drug list
It is crucial that the public health institutions are supportive of the process and believe in the integrity of the final RDL in order to promote the adherence to it by prescribers and institutions
10/06/09 MeTA

MeTA Work plan- Jordan
Encouraging best practice/ improve rational use of medicines
Evidence based decision making for the rational drug list RDL
Capacity building in Civil society
10/06/09 MeTA

Evidence- based decision making can be achieved through:
Assessment of Current Committees’ constitution, TOR and Procedures
Assessment of current classification of drugs
Raising awareness among stakeholders and building capacity
Monitoring & evaluation
10/06/09 MeTA

Assessment of Current Committees’ constitution, TOR and Procedures sub-activities:
Review constitutions, TOR and SOPs of various committees involved in the selection of drugs in the RDL (requires COI declaration, and COI guidelines) and benchmark against best practices
Recommend regulations for the amendments- if needed
Review criteria for adding and deleting drugs to and from the RDL
Recommend evidence based regulations for the addition / deletion criteria
Adopt the recommendations
10/06/09 MeTA

Assessment of current classification of drugs
Formulate a technical working group to review the classification of drugs (restricted, unrestricted & authority required) in the RDL
Recommend detailed evidence based regulations for the implementation of the classification of drugs
Adopt the classification & the detailed regulations for the implementation of the classification
10/06/09 MeTA

Technical working group represents
JFDA/ RDU
JPD
Ministry of Health/ Clinical Pharmacy , Supply Departments
Royal Medical Services/ Drug &Pharmacy, Supply Departments
Academia/ PhD in clinical pharmacy
Internal medicine consultant
Pharmaco-economist
10/06/09 MeTA

Raising awareness among stakeholders and building capacity
Organize workshops to raise awareness and reach a common understanding on the concepts of role of pharmacy & therapeutic committee (PTC), evidence-based medicine (EBM), pharmaco-economics, transparency & accountability
Train policy makers and technical committees in NICE/UK
Organize workshop on use of cost effectiveness tools
10/06/09 MeTA

Monitoring and Evaluation
Monitor and Evaluate the adoption and implementation of recommendations in previous activities, according to set KPI’s
10/06/09 MeTA

Evidence- based decision making activities KPI’s include:
Constitution, TOR & SOPs for committees are in place
Guidelines for addition/ deletion & classification are in place
Workshops conducted
Reports to be delivered
10/06/09 MeTA

Thank you 10/06/09 MeTA

Evidence based decision making for the rational drug list (RDL)

by MeTApresents on Jun 08, 2009

Accessibility

Categories

Tags

Upload Details

Usage Rights

1 Embed 4

Statistics

Evidence based decision making for the rational drug list (RDL) — Presentation Transcript